TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00751023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 tablets daily for 4 weeks
Study: NCT03509662
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
Study: NCT03509662
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group receives a placebo.
Study: NCT02201316
Drug: GR107719B (Formulation 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
Study: NCT02201316
Drug: GR107719B (Formulation 2)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
Study: NCT00759707
Drug: L-N^G monomethyl arginine (L-NMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
Study: NCT02208973
Drug: PBF-680
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5, 10, 20, 40 and 60 mg of PBF-680
Study: NCT02208973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
Study: NCT00615615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
Study: NCT01468688
Drug: STI571
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01468688
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 combination therapy
Study: NCT00948909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention
Study: NCT00948909
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental intervention
Study: NCT00842309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
Study: NCT04691505
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is used as the reference group.
Study: NCT00088517
Drug: [11C]NNC-112
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05745584
Drug: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
Study: NCT00427154
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT00204451
Drug: 50 mg ethinyl estradiol/0.5 mg levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01742208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
Study: NCT04173923
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
Study: NCT01929915
Drug: Intravenous patient controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
Study: NCT01409603
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT04586985
Drug: FTX-6058/placebo oral capsule(s)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive FTX-6058 or matching placebo.
Study: NCT04586985
Drug: FTX-6058 - Two Dosing Periods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive FTX-6058
Study: NCT00693160
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single intrathecal injection of ketorolac 2 mg
Study: NCT00693160
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subject will receive a placebo (preservative free normal saline) spinal injection
Study: NCT00693160
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive a remifentanil infusion
Study: NCT00820573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 6 weeks
Study: NCT02063035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single topical application of matching placebo, which is 100 mL of normal saline.
Study: NCT01129258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
Study: NCT03423771
Drug: NPF-08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution
Study: NCT00973973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets taken orally once a day
Study: NCT00817063
Drug: alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
Study: NCT00817063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive matching placebo for up to 24 weeks
Study: NCT02772588
Drug: ARN-509
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03332732
Drug: VNRX-5133
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactamase inhibitor
Study: NCT03332732
Drug: VNRX-5022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approved β-lactam antibiotic
Study: NCT03332732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching VNRX-5133 + VNRX-5022)
Study: NCT05025163
Drug: 1.23% fluoride foam application
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application of fluoride foam every 6 months
Study: NCT05025163
Drug: 2.26% fluoride varnish application
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application of fluoride varnish every 6 months
Study: NCT04172558
Drug: Trimix
Normalized name: Nutrimix Mac Vented
Approvals — FDA: no, EMA: no, PMDA: no
Description: on demand ICI of Trimix
Study: NCT02981069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Dapagliflozin
Study: NCT03623867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take placebo once weekly in week 0-4, and once monthly till week 48
Study: NCT04608487
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT01958008
Drug: Placebo to BI 113608 high dose b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01958008
Drug: Placebo to BI 113608 low dose b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01958008
Drug: BI 113608 high dose b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01958008
Drug: Placebo to BI 113608 medium dose b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01958008
Drug: BI 113608 low dose b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01958008
Drug: BI 113608 medium dose b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT03552263
Drug: T89 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: T89 capsules (75mg), orally, twice daily.
Study: NCT03552263
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (0mg), orally, twice daily.
Study: NCT02028065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a single IV bolus over 10 seconds
Study: NCT01414855
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
Study: NCT01414855
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
Study: NCT03957681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q2W, SC
Study: NCT01971554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, capsules, oral, QD, Days 1 to 14
Study: NCT01102660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg once daily for 2 weeks
Study: NCT01102660
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, 500 mg twice daily for 2 weeks
Study: NCT01102660
Drug: Naproxen + PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
Study: NCT02892071
Drug: 22% TCA peel
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
Study: NCT02571257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00765635
Drug: drops intilation (Taponoto ® )
Approvals — FDA: no, EMA: no, PMDA: no
Description: four drops, unique doses
Study: NCT00765635
Drug: drops intilation (Otocerum®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: four drops, unique doses
Study: NCT00044876
Drug: CDB-2914
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02641873
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg twice daily (480 mg total daily dose)
Study: NCT00526136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01568203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo control for AMG 579 at each dose level
Study: NCT01026597
Drug: REGN727
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)
Study: NCT01026597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)
Study: NCT02614196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00805896
Drug: Songyou
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g/pack
Study: NCT00805896
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g/pack
Study: NCT01277640
Drug: universal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * dosage form: gel, HEC-based~* dosage: 2.5g~* frequency: once daily~* duration: 7 days
Study: NCT00718224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study: NCT00000321
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002909
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01773785
Drug: SPI-1620
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
Study: NCT00956254
Drug: Fentanyl sublingual spray
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
Study: NCT01678677
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT03685409
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch Placebo oral tablets will be given once daily to the control group
Study: NCT00361595
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg zoledronic acid administered in a single 15 minute IV
Study: NCT00535925
Drug: SoC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients have to be treated according the standard good medical practice by any center
Study: NCT02396888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the wound surface was treated daily with 0.1 cc of normal saline.
Study: NCT00535925
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapy for hypercholesterolemia:~- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die
Study: NCT01614093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- Sugar pill
Study: NCT04097444
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04097444
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02380755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill orally daily during 12 weeks
Study: NCT02579226
Drug: AZD2811
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
Study: NCT02502643
Drug: OK-432 pleurodesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
Study: NCT02796105
Drug: Progevera
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02131077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02856594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00140595
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00140595
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05063630
Drug: Medical treatment alone
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
Study: NCT00835796
Drug: PROSCAR® 5mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 5 mg, single dose fasting
Study: NCT02095522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02343627
Drug: NVXT Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Study: NCT04208698
Drug: Placebo for CIN-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00159471
Drug: capecitabine, gemcitabine, docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00076284
Drug: GW873140
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00576927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00014469
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02654522
Drug: Hylenex
Normalized name: Hylenex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
Study: NCT00774644
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00965757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
Study: NCT00225173
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
Study: NCT00225173
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
Study: NCT02384889
Drug: Difluoromethylornithine
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Therapy with DFMO
Study: NCT02384889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparitor
Study: NCT02356224
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
Study: NCT02356224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
Study: NCT02164812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03329950
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
Study: NCT00540826
Drug: stimulants (any approved ADHD medication)
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: in-label use
Study: NCT03942848
Drug: zicotinide followed by placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
Study: NCT03942848
Drug: Placebo followed by zicotinide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
Study: NCT03057431
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 3 years
Study: NCT03057431
Drug: 12.5 mg hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 3 years
Study: NCT03057431
Drug: 25.0 mg hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 3 years
Study: NCT03057431
Drug: 50.0 mg hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 3 years
Study: NCT01217840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill - 3 pills every 12 weeks for total of 24 weeks
Study: NCT00935753
Drug: sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
Study: NCT01754623
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
Study: NCT02429583
Drug: Recombivax
Normalized name: Recombivax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
Study: NCT03275376
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin or placebo will be administered according to randomized allocations.
Study: NCT01798004
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV